Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer. It is usually treated
with surgery and adjuvant radiotherapy. While radiotherapy helps to prevent local recurrence
of the disease, it can also cause acute and late adverse effects. The inflammatory response
plays an important role in this process, as irradiation induces the formation of reactive
oxygen species, which damage cellular macromolecules and affect numerous cellular
processes associated with the cellular stress response. Patients respond differently to
radiotherapy, which may also be influenced by genetic variability in inflammatory pathways.
The aim of this master’s thesis was to investigate whether genetic variability in inflammatory
pathways is associated with the occurrence of acute and late adverse effects of radiotherapy
in patients with DCIS.
The prospective longitudinal study included 199 patients with DCIS who were treated at the
Oncology Institute in Ljubljana. Skin and cardiac adverse effects of radiotherapy were
evaluated immediately after treatment and one year later. DNA isolated from patients’ whole
blood samples was analyzed using competitive allele-specific PCR to determine the presence
of polymorphisms in key genes related to the inflammatory response (CARD8, NLRP3, IL1B,
MIR146A, IL6, IL6R, TNF). Bioinformatic tools were used to examine the biological
processes in which these genes are involved and how they interact with each other.
Based on the results we found that the polymorphisms IL6R rs2228145 and IL6 rs1800795
influence the occurrence of acute skin adverse effects after radiotherapy. We also observed
an association between polymorphisms rs1143623 and rs16944 in the IL1B gene and the
likelihood of late adverse effects. In addition, we observed an association between IL1B
rs1071676 and MIR146A rs2910164 polymorphisms and the occurrence of acute cardiac
adverse effects. These findings support the hypothesis that genetic variability in
inflammatory pathways significantly influences the risk of side effects from radiotherapy.
These findings might contribute to the personalization of DCIS treatment in the future. To
achieve this goal, further studies are needed to confirm the relationship between genetic
factors and treatment response.
|